Acute myeloid leukaemia after treatment with90Y-ibritumomab tiuxetan for follicular lymphoma

2008 ◽  
Vol 26 (3) ◽  
pp. 179-181 ◽  
Author(s):  
Daniele Focosi ◽  
Nadia Cecconi ◽  
Giuseppe Boni ◽  
Enrico Orciuolo ◽  
Sara Galimberti ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Follicular Lymphoma ◽  
Myeloid Leukaemia ◽  
Ibritumomab Tiuxetan ◽  
Acute Myeloid

scholarly journals Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma

2017 ◽  
Vol 178 (3) ◽  
pp. 427-433 ◽  
Author(s):  
Narendranath Epperla ◽  
Anthony Q. Pham ◽  
Brian L. Burnette ◽  
Gregory A. Wiseman ◽  
Thomas M. Habermann ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Follicular Lymphoma ◽  
Myeloid Leukaemia ◽  
Histological Transformation ◽  
Acute Myeloid

The acute myeloid leukaemia market

2019 ◽  
Vol 19 (4) ◽  
pp. 233-234
Author(s):  
Jorrit Schaefer ◽  
Sorcha Cassidy ◽  
Rachel M. Webster
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Myeloid

Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome

2005 ◽  
Vol 44 (03) ◽  
pp. 107-117
Author(s):  
R. G. Meyer ◽  
W. Herr ◽  
A. Helisch ◽  
P. Bartenstein ◽  
I. Buchmann
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Primary Tumour ◽  
The Other ◽  
Haematopoietic Stem Cell ◽  
Other Hand ◽  
Primary Reduction ◽  
The One ◽  
Acute Myeloid

SummaryThe prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term diseasefree survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT.This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.

Sign in / Sign up

Export Citation Format

Share Document